BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

BC

#5

PCT09

RAW SEQUENCE LISTING DATE: 10/29/2001
PATENT APPLICATION: US/09/869,003 TIME: 11:51:13

Input Set : A:\Nih386-2.app
Output Set: N:\CRF3\10292001\I869003.raw

<110> APPLICANT: Scala, Giuseppe
Chen, Xueni
Cohen, Oren J.
Fauci, Anthony
The Government of the United States of America
as represented by the Secretary of the
Department of Health and Human Services
<120> TITLE OF INVENTION: Novel HIV Related Peptides
<130> FILE REFERENCE: 015280-386200US
<140> CURRENT APPLICATION NUMBER: US 09/869,003 OK
<141> CURRENT FILING DATE: 2001-06-22
<150> PRIOR APPLICATION NUMBER: US 60/115,430
<151> PRIOR FILING DATE: 1999-01-11
<150> PRIOR APPLICATION NUMBER: US 60/132,760
<151> PRIOR FILING DATE: 1999-05-06
<150> PRIOR APPLICATION NUMBER: WO PCT/US00/00372
<151> PRIOR FILING DATE: 2000-01-07
<160> NUMBER OF SEQ ID NOS: 34
<170> SOFTWARE: PatentIn Ver. 2.1
<210> SEQ ID NO: 1
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antigenic determinant peptide
<220> FEATURE:
<221> NAME/KEY: MOD_RES
<222> LOCATION: (1)
<223> OTHER INFORMATION: Xaa = any amino acid not identical to the amino acid naturally flanking the subsequence at positions 2-10 in HIV-1
<220> FEATURE:
<221> NAME/KEY: MOD_RES
<222> LOCATION: (11)
<223> OTHER INFORMATION: Xaa = any amino acid not identical to the amino acid naturally flanking the subsequence at positions 2-10 in HIV-1
<400> SEQUENCE: 1
W--> **Xaa Lys Ser Ser Gly Lys Leu Ile Ser Leu Xaa**
1 5 10
<210> SEQ ID NO: 2
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antigenic

ENTERED

P.5

RAW SEQUENCE LISTING DATE: 10/29/2001
PATENT APPLICATION: US/09/869,003 TIME: 11:51:13

Input Set : A:\Nih386-2.app
Output Set: N:\CRF3\10292001\I869003.raw

```
     66       determinant peptide
     68 <220> FEATURE:
     69 <221> NAME/KEY: MOD_RES
     70 <222> LOCATION: (1)
     71 <223> OTHER INFORMATION: Xaa = any amino acid not identical to the amino
     72       acid naturally flanking the subsequence at positions
     73       2-10 in HIV-1
     75 <220> FEATURE:
     76 <221> NAME/KEY: MOD_RES
     77 <222> LOCATION: (11)
     78 <223> OTHER INFORMATION: Xaa = any amino acid not identical to the amino
     79       acid naturally flanking the subsequence at positions
     80       2-10 in HIV-1
     82 <400> SEQUENCE: 2
W--> 83 Xaa Cys Asn Gly Arg Leu Tyr Cys Gly Pro Xaa
     84   1               5                  10
     87 <210> SEQ ID NO: 3
     88 <211> LENGTH: 11
     89 <212> TYPE: PRT
     90 <213> ORGANISM: Artificial Sequence
     92 <220> FEATURE:
     93 <223> OTHER INFORMATION: Description of Artificial Sequence:antigenic
     94       determinant peptide
     96 <220> FEATURE:
     97 <221> NAME/KEY: MOD_RES
     98 <222> LOCATION: (1)
     99 <223> OTHER INFORMATION: Xaa = any amino acid not identical to the amino
    100       acid naturally flanking the subsequence at positions
    101       2-10 in HIV-1
    103 <220> FEATURE:
    104 <221> NAME/KEY: MOD_RES
    105 <222> LOCATION: (11)
    106 <223> OTHER INFORMATION: Xaa = any amino acid not identical to the amino
    107       acid naturally flanking the subsequence at positions
    108       2-10 in HIV-1
    110 <400> SEQUENCE: 3
W--> 111 Xaa Gly Thr Lys Leu Val Cys Phe Ala Ala Xaa
    112   1               5                  10
    115 <210> SEQ ID NO: 4
    116 <211> LENGTH: 9
    117 <212> TYPE: PRT
    118 <213> ORGANISM: Artificial Sequence
    120 <220> FEATURE:
    121 <223> OTHER INFORMATION: Description of Artificial Sequence:p195 epitope
    122       antigenic determinant peptide
    124 <400> SEQUENCE: 4
    125 Lys Ser Ser Gly Lys Leu Ile Ser Leu
    126   1               5
    129 <210> SEQ ID NO: 5
```

RAW SEQUENCE LISTING DATE: 10/29/2001
PATENT APPLICATION: US/09/869,003 TIME: 11:51:13

Input Set : A:\Nih386-2.app
Output Set: N:\CRF3\10292001\I869003.raw

<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:p217 epitope antigenic determinant peptide
<400> SEQUENCE: 5
Cys Asn Gly Arg Leu Tyr Cys Gly Pro
1 5
<210> SEQ ID NO: 6
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:p197 epitope antigenic determinant peptide
<400> SEQUENCE: 6
Gly Thr Lys Leu Val Cys Phe Ala Ala
1 5
<210> SEQ ID NO: 7
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antigenic determinant peptide
<400> SEQUENCE: 7
Glu Ala Thr Val Val Tyr Pro Ala Pro
1 5
<210> SEQ ID NO: 8
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:p54 epitope with no obvious sequence homology with HIV protein domains
<400> SEQUENCE: 8
Thr Lys Thr Leu Ile Tyr Gly Gly Ala
1 5
<210> SEQ ID NO: 9
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:p163 epitope with no obvious sequence homology with HIV protein domains
<400> SEQUENCE: 9

RAW SEQUENCE LISTING DATE: 10/29/2001
PATENT APPLICATION: US/09/869,003 TIME: 11:51:13

Input Set : A:\Nih386-2.app
Output Set: N:\CRF3\10292001\I869003.raw

```
197 Lys Arg Ile Val Ile Gly Pro Gln Thr
198   1               5
201 <210> SEQ ID NO: 10
202 <211> LENGTH: 9
203 <212> TYPE: PRT
204 <213> ORGANISM: Artificial Sequence
206 <220> FEATURE:
207 <223> OTHER INFORMATION: Description of Artificial Sequence:antigenic
208       determinant peptide
210 <400> SEQUENCE: 10
211 Cys Cys Gly Cys Leu Thr Cys Ser Val
212   1               5
215 <210> SEQ ID NO: 11
216 <211> LENGTH: 10
217 <212> TYPE: PRT
218 <213> ORGANISM: Artificial Sequence
220 <220> FEATURE:
221 <223> OTHER INFORMATION: Description of Artificial Sequence:antigenic
222       determinant peptide
224 <400> SEQUENCE: 11
225 Ser Gly Arg Leu Tyr Cys His Glu Ser Trp
226   1               5                  10
229 <210> SEQ ID NO: 12
230 <211> LENGTH: 9
231 <212> TYPE: PRT
232 <213> ORGANISM: Artificial Sequence
234 <220> FEATURE:
235 <223> OTHER INFORMATION: Description of Artificial Sequence:antigenic
236       determinant peptide
238 <400> SEQUENCE: 12
239 Phe Ala Leu Ser His Tyr Asp Lys Pro
240   1               5
243 <210> SEQ ID NO: 13
244 <211> LENGTH: 9
245 <212> TYPE: PRT
246 <213> ORGANISM: Artificial Sequence
248 <220> FEATURE:
249 <223> OTHER INFORMATION: Description of Artificial Sequence:p689 epitope
250       with no obvious sequence homology with HIV protein
251       domains
253 <400> SEQUENCE: 13
254 Arg Pro Thr Leu Arg Phe Gln Gly Ala
255   1               5
258 <210> SEQ ID NO: 14
259 <211> LENGTH: 20
260 <212> TYPE: PRT
261 <213> ORGANISM: Artificial Sequence
263 <220> FEATURE:
264 <223> OTHER INFORMATION: Description of Artificial Sequence:p195 analog
```

RAW SEQUENCE LISTING DATE: 10/29/2001
PATENT APPLICATION: US/09/869,003 TIME: 11:51:13

Input Set : A:\Nih386-2.app
Output Set: N:\CRF3\10292001\I869003.raw

```
265       antigenic determinant peptide
267 <400> SEQUENCE: 14
268 Glu Gly Glu Phe Cys Lys Ser Ser Gly Lys Leu Ile Ser Leu Cys Gly
269   1               5                  10                  15
271 Asp Pro Ala Lys
272              20
275 <210> SEQ ID NO: 15
276 <211> LENGTH: 20
277 <212> TYPE: PRT
278 <213> ORGANISM: Artificial Sequence
280 <220> FEATURE:
281 <223> OTHER INFORMATION: Description of Artificial Sequence:p197 analog
282       antigenic determinant peptide
284 <400> SEQUENCE: 15
285 Glu Gly Glu Phe Cys Gln Thr Lys Leu Val Cys Phe Ala Ala Ala Gly
286   1               5                  10                  15
288 Asp Pro Ala Lys
289              20
292 <210> SEQ ID NO: 16
293 <211> LENGTH: 20
294 <212> TYPE: PRT
295 <213> ORGANISM: Artificial Sequence
297 <220> FEATURE:
298 <223> OTHER INFORMATION: Description of Artificial Sequence:p217 analog
299       antigenic determinant peptide
301 <400> SEQUENCE: 16
302 Glu Gly Glu Phe Cys Cys Asn Gly Arg Leu Tyr Cys Gln Pro Cys Gly
303   1               5                  10                  15
305 Asp Pro Ala Lys
306              20
309 <210> SEQ ID NO: 17
310 <211> LENGTH: 20
311 <212> TYPE: PRT
312 <213> ORGANISM: Artificial Sequence
314 <220> FEATURE:
315 <223> OTHER INFORMATION: Description of Artificial Sequence:p287 analog
316       antigenic determinant peptide
318 <400> SEQUENCE: 17
319 Glu Gly Glu Phe Cys Cys Ala Gly Gln Leu Thr Cys Ser Val Cys Gly
320   1               5                  10                  15
322 Asp Pro Ala Lys
323              20
326 <210> SEQ ID NO: 18
327 <211> LENGTH: 12
328 <212> TYPE: PRT
329 <213> ORGANISM: Artificial Sequence
331 <220> FEATURE:
332 <223> OTHER INFORMATION: Description of Artificial Sequence:p335 analog
333       antigenic determinant peptide
```

Use of n and / or Xaa has been detected in the Sequence Listing. Review the Sequence Listing to ensure a corresponding explanation is present in the <220> to <223> fields of each sequence using n or Xaa.

VERIFICATION SUMMARY DATE: 10/29/2001
PATENT APPLICATION: US/09/869,003 TIME: 11:51:14

Input Set : A:\Nih386-2.app
Output Set: N:\CRF3\10292001\I869003.raw

L:55 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:83 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:111 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:539 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:542 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:545 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:548 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:551 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:554 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:557 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:585 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
L:588 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
L:591 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
L:594 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
L:597 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
L:600 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
L:603 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
L:631 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:634 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:637 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:640 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:643 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:646 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:649 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33